不可切除胰腺癌的分子靶向药物治疗进展

胡润; 李俊蒽; 姚沛; 桂仁捷; 段华新

doi:10.12449/JCH240234

不可切除胰腺癌的分子靶向药物治疗进展

DOI: 10.12449/JCH240234

湖南师范大学附属第一医院，湖南省人民医院肿瘤科，长沙 410005

基金项目:

湖南省自然科学基金 (2020JJ8084)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：胡润负责资料收集，分析数据及撰写文章；李俊蒽、姚沛参与文章修改；桂仁捷参与文章框架构思；段华新指导文章撰写及审校。

详细信息

通信作者:
段华新， 317102912@qq.com （ORCID： 0000-0001-9596-5013）

计量
- 文章访问数: 299
- HTML全文浏览量: 108
- PDF下载量: 65
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-30
- 录用日期: 2023-08-21
- 出版日期: 2024-02-19

Advances in molecular-targeted therapy for unresectable pancreatic cancer

Department of Oncology，The First Affiliated Hospital of Hunan Normal University，Hunan Provincial People’s Hospital，Changsha 410005，China

Research funding:

Natural Science Foundation of Hunan Province of China (2020JJ8084)

More Information

Corresponding author: DUAN Huaxin， 317102912@qq.com （ORCID： 0000-0001-9596-5013）

摘要

摘要: 胰腺癌作为消化系统最常见的恶性肿瘤之一，其发病率及死亡率正逐年上升，大多数胰腺癌患者因分期较晚而失去了手术机会。尽管以吉西他滨、氟尿嘧啶为主的化疗方案在一定程度上延长了患者的生存期，但仍有部分患者因无法耐受化疗而失去治疗机会。随着精准医疗时代的来临，分子靶向药物治疗展现出的优异疗效使其成为对抗肿瘤的重要治疗手段之一，但由于胰腺癌高度的异质性及复杂的免疫微环境，针对胰腺癌的分子靶向治疗并未取得显著效果，因此亟需探寻新的治疗靶点及药物攻克这一难题。本综述基于胰腺癌常见分子靶点及肿瘤免疫相关靶点探究在不可切除胰腺癌中分子靶向药物治疗研究的最新进展，为胰腺癌患者提供新的治疗策略。
- 胰腺肿瘤 /
- 分子靶向治疗 /
- 免疫疗法
Abstract: Pancreatic cancer is one of the most prevalent malignant tumors of the digestive system， and its incidence and mortality rates are increasing year by year. Most patients with pancreatic cancer are unable to receive surgery due to the advanced stage. Although chemotherapy regimens based on gemcitabine and fluorouracil have prolonged the survival time of patients to some extent， some patients cannot tolerate chemotherapy and hence lose the opportunity for treatment. With the advent of the era of precision medicine， molecular-targeted therapy has exhibited an excellent therapeutic efficacy and has thus become one of the most important treatment techniques for tumors； however， due to the high heterogeneity of pancreatic cancer and its complicated tumor microenvironment， molecular-targeted therapy for pancreatic cancer has not achieved notable results. Therefore， it is imperative to seek new therapeutic targets and medications to overcome this issue. This article reviews the latest advances in the research on molecular-targeted therapy for unresectable pancreatic cancer based on common molecular targets and tumor immunity-related therapeutic targets， in order to provide new treatment strategies for patients with pancreatic cancer.
- Pancreatic Neoplasms /
- Molecular Targeted Therapy /
- Immunotherapy

HTML全文

参考文献(46)

[1]	XIA CF, DONG XS, LI H, et al. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants[J]. Chin Med J(Engl), 2022, 135( 5): 584- 590. DOI: 10.1097/CM9.0000000000002108.
[2]	PARK W, CHAWLA A, O’REILLY EM. Pancreatic cancer: A review[J]. JAMA, 2021, 326( 9): 851- 862. DOI: 10.1001/jama.2021.13027.
[3]	CONROY T, HAMMEL P, HEBBAR M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer[J]. N Engl J Med, 2018, 379( 25): 2395- 2406. DOI: 10.1056/NEJMoa1809775.
[4]	ZHANG ZN, ZHANG H, LIAO X, et al. KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression[J]. Front Cell Dev Biol, 2023, 11: 1147676. DOI: 10.3389/fcell.2023.1147676.
[5]	STRICKLER JH, SATAKE H, GEORGE TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer[J]. N Engl J Med, 2023, 388( 1): 33- 43. DOI: 10.1056/nejmoa2208470.
[6]	SI OU, JÄNNE PA, LEAL TA, et al. First-in-human phase I/IB dose-finding study of adagrasib(MRTX849) in patients with advanced KRAS^G12C solid tumors(KRYSTAL-1)[J]. J Clin Oncol, 2022, 40( 23): 2530- 2538. DOI: 10.1200/JCO.21.02752.
[7]	WATERS AM, DER CJ. KRAS: The critical driver and therapeutic target for pancreatic cancer[J]. Cold Spring Harb Perspect Med, 2018, 8( 9): a031435. DOI: 10.1101/cshperspect.a031435.
[8]	KEMP SB, CHENG N, MARKOSYAN N, et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer[J]. Cancer Discov, 2023, 13( 2): 298- 311. DOI: 10.1158/2159-8290.CD-22-1066.
[9]	SHIN JE, AN HJ, PARK HS, et al. Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report[J]. Front Oncol, 2022, 12: 976450. DOI: 10.3389/fonc.2022.976450.
[10]	LI HS, YANG K, WANG Y. Remarkable response of BRAF^V600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: A case report[J]. Gastroenterol Rep(Oxf), 2022, 10: goab031. DOI: 10.1093/gastro/goab031.
[11]	SALAMA AKS, LI S, MACRAE ER, et al. Dabrafenib and trametinib in patients with tumors with BRAF^V600E mutations: Results of the NCI-MATCH trial subprotocol H[J]. J Clin Oncol, 2020, 38( 33): 3895- 3904. DOI: 10.1200/JCO.20.00762.
[12]	SUBBIAH V, LASSEN U, ÉLEZ E, et al. Dabrafenib plus trametinib in patients with BRAF^V600E-mutated biliary tract cancer(ROAR): A phase 2, open-label, single-arm, multicentre basket trial[J]. Lancet Oncol, 2020, 21( 9): 1234- 1243. DOI: 10.1016/S1470-2045(20)30321-1.
[13]	COCCO E, SCALTRITI M, DRILON A. NTRK fusion-positive cancers and TRK inhibitor therapy[J]. Nat Rev Clin Oncol, 2018, 15( 12): 731- 747. DOI: 10.1038/s41571-018-0113-0.
[14]	DOEBELE RC, DRILON A, PAZ-ARES L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020, 21( 2): 271- 282. DOI: 10.1016/S1470-2045(19)30691-6.
[15]	HONG DS, DUBOIS SG, KUMMAR S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials[J]. Lancet Oncol, 2020, 21( 4): 531- 540. DOI: 10.1016/S1470-2045(19)30856-3.
[16]	MOORE MJ, GOLDSTEIN D, HAMM J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25( 15): 1960- 1966. DOI: 10.1200/JCO.2006.07.9525.
[17]	LIU Y, GUO YL, WU ZQ, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial[J]. Cytotherapy, 2020, 22( 10): 573- 580. DOI: 10.1016/j.jcyt.2020.04.088.
[18]	KOUMARIANOU A, KALTSAS G. Surufatinib-a novel oral agent for neuroendocrine tumours[J]. Nat Rev Endocrinol, 2021, 17( 1): 9- 10. DOI: 10.1038/s41574-020-00439-0.
[19]	BAGHDADI T AL, HALABI S, GARRETT-MAYER E, et al. Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study[J]. JCO Precis Oncol, 2019, 3: 1- 8. DOI: 10.1200/PO.19.00124.
[20]	KATO S, ADASHEK JJ, SHAYA J, et al. Concomitant MEK and cyclin gene alterations: Implications for response to targeted therapeutics[J]. Clin Cancer Res, 2021, 27( 10): 2792- 2797. DOI: 10.1158/1078-0432.CCR-20-3761.
[21]	BLAIR AB, GROOT VP, GEMENETZIS G, et al. BRCA1/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma[J]. J Am Coll Surg, 2018, 226( 4): 630- 637. DOI: 10.1016/j.jamcollsurg.2017.12.021.
[22]	KINDLER HL, HAMMEL P, RENI M, et al. Overall survival results from the POLO trial: A phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer[J]. J Clin Oncol, 2022, 40( 34): 3929- 3939. DOI: 10.1200/JCO.21.01604.
[23]	REISS KA, MICK R, TEITELBAUM U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: A randomised, phase 1b/2 trial[J]. Lancet Oncol, 2022, 23( 8): 1009- 1020. DOI: 10.1016/S1470-2045(22)00369-2.
[24]	FEIG C, JONES JO, KRAMAN M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer[J]. Proc Natl Acad Sci U S A, 2013, 110( 50): 20212- 20217. DOI: 10.1073/pnas.1320318110.
[25]	BOCKORNY B, SEMENISTY V, MACARULLA T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: The COMBAT trial[J]. Nat Med, 2020, 26( 6): 878- 885. DOI: 10.1038/s41591-020-0880-x.
[26]	BAILEY P, CHANG DK, NONES K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer[J]. Nature, 2016, 531( 7592): 47- 52. DOI: 10.1038/nature16965.
[27]	MELISI D, GARCIA-CARBONERO R, MACARULLA T, et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer[J]. Br J Cancer, 2018, 119( 10): 1208- 1214. DOI: 10.1038/s41416-018-0246-z.
[28]	MELISI D, OH DY, HOLLEBECQUE A, et al. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer[J]. J Immunother Cancer, 2021, 9( 3): e002068. DOI: 10.1136/jitc-2020-002068.
[29]	WANG X, ZHANG CS, DONG XY, et al. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma[J]. World J Gastrointest Oncol, 2022, 14( 7): 1252- 1264. DOI: 10.4251/wjgo.v14.i7.1252.
[30]	QI CS, GONG JF, LI J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results[J]. Nat Med, 2022, 28( 6): 1189- 1198. DOI: 10.1038/s41591-022-01800-8.
[31]	LIU YF, SUN YS, WANG P, et al. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer[J]. J Transl Med, 2023, 21( 1): 255. DOI: 10.1186/s12967-023-04080-z.
[32]	YANG YM, DONG RH, ZHANG XS, et al.‘Oasis’ in‘death desert’: attach importance to the diagnosis and treatment for pancreatic cancer with microsatellite instability-high/deficient mismatch repair[J]. Chin J Dig Surg, 2023, 22( 5): 588- 592. DOI: 10.3760/cma.j.cn115610-20230505-00194. 杨尹默, 董睿涵, 张兴胜, 等.“死亡荒漠”的“绿洲”: 重视微卫星高度不稳定/错配修复缺陷胰腺癌的诊断与治疗[J]. 中华消化外科杂志, 2023, 22( 5): 588- 592. DOI: 10.3760/cma.j.cn115610-20230505-00194.
[33]	ULLMAN NA, BURCHARD PR, DUNNE RF, et al. Immunologic strategies in pancreatic cancer: Making cold tumors hot[J]. J Clin Oncol, 2022, 40( 24): 2789- 2805. DOI: 10.1200/JCO.21.02616.
[34]	PADRÓN LJ, MAURER DM, O’HARA MH, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial[J]. Nat Med, 2022, 28( 6): 1167- 1177. DOI: 10.1038/s41591-022-01829-9.
[35]	CHEN IM, JOHANSEN JS, THEILE S, et al. Randomized phase Ⅱ study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer(CheckPAC)[J]. J Clin Oncol, 2022, 40( 27): 3180- 3189. DOI: 10.1200/JCO.21.02511.
[36]	CHEN BT, MAO XH. Clinical research advance in immunotherapy of pancreatic cancer[J]. Chin J Dig Surg, 2023, 22( 5): 610- 615. DOI: 10.3760/cma.j.cn115610-20230407-00158. 陈博滔, 毛先海. 胰腺癌免疫治疗临床研究进展[J]. 中华消化外科杂志, 2023, 22( 5): 610- 615. DOI: 10.3760/cma.j.cn115610-20230407-00158.
[37]	YAN C, RICHMOND A. Hiding in the dark: Pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy[J]. Mol Cancer, 2021, 20( 1): 146. DOI: 10.1186/s12943-021-01442-3.
[38]	BEATTY GL, CHIOREAN EG, FISHMAN MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans[J]. Science, 2011, 331( 6024): 1612- 1616. DOI: 10.1126/science.1198443.
[39]	VAN LAETHEM J, BORBATH I, PRENEN H, et al. Mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma(PDAC): Safety data from part of the OPTIMIZE-1 study[Z]. American Society of Clinical Oncology, 2022.
[40]	LIU HC, DAVILA GONZALEZ D, VISWANATH DI, et al. Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer[J]. Adv Sci(Weinh), 2023, 10( 9): e2206873. DOI: 10.1002/advs.202206873.
[41]	SHANKARA NARAYANAN JS, HAYASHI T, ERDEM S, et al. Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model[J]. J Immunother Cancer, 2023, 11( 1): e006133. DOI: 10.1136/jitc-2022-006133.
[42]	HAMIDI H, IVASKA J. Every step of the way: Integrins in cancer progression and metastasis[J]. Nat Rev Cancer, 2018, 18( 9): 533- 548. DOI: 10.1038/s41568-018-0038-z.
[43]	DEAN A, GILL S, MCGREGOR M, et al. Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: A first-in-human, open-label, multicentre, phase 1 study[J]. Lancet Gastroenterol Hepatol, 2022, 7( 10): 943- 951. DOI: 10.1016/S2468-1253(22)00167-4.
[44]	DAWSON JC, SERRELS A, STUPACK DG, et al. Targeting FAK in anticancer combination therapies[J]. Nat Rev Cancer, 2021, 21( 5): 313- 324. DOI: 10.1038/s41568-021-00340-6.
[45]	JIANG H, HEGDE S, KNOLHOFF BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy[J]. Nat Med, 2016, 22( 8): 851- 860. DOI: 10.1038/nm.4123.
[46]	WANG-GILLAM A, LIM KH, MCWILLIAMS R, et al. Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: A phase I dose escalation and expansion study[J]. Clin Cancer Res, 2022, 28( 24): 5254- 5262. DOI: 10.1158/1078-0432.CCR-22-0308.